Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital

Vox Sanguinis

Volumn 111, Issue 1, 2016, Pages 55-61

  Shander, A ^a,b   Ozawa, S ^a   Hofmann, A ^a,c,d,e  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

blood collection; plasma; transfusion medicine (general)

Indexed keywords

FRESH FROZEN PLASMA;

ACTIVITY BASED COSTING; ARTICLE; BLOOD CLOTTING DISORDER; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; ERYTHROCYTE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PLASMA TRANSFUSION; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOCYTE; UNITED STATES;

EID: 84977591177     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12386     Document Type: Article

References (50)

1. Liumbruno G, Bennardello F, Lattanzio A, et al.: Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009; 7:132–150
2. Stainsby D, MacLennan S, Thomas D, et al.: Guidelines on the management of massive blood loss. Br J Haematol 2006; 135:634–641
3. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11–28
4. Tran HA, Chunilal SD, Harper PL, et al.: An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198:198–199
5. Scully M, Hunt BJ, Benjamin S, et al.: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323–335
6. AABB, ARC, ABC, et al.: Circular of information: for the use of human blood and blood components. 2013; http://www.aabb.org/tm/coi/Documents/coi1113.pdf
7. Benjamin RJ, McLaughlin LS: Plasma components: properties, differences, and uses. Transfusion 2012; 52(Suppl 1):9S–19S
8. Desborough M, Stanworth S: Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures. Transfusion 2012; 52(Suppl 1):20S–29S
9. Huisman EL, van Eerd MC, Ouwens JN, et al.: Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG(R)) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci 2014; 51:25–34
10. Labarinas S, Arni D, Karam O: Plasma in the PICU: why and when should we transfuse? Ann Intensive Care 2013; 3:16
11. Lin Y, Saw CL, Hannach B, et al.: Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012; 52:567–574
12. Narick C, Triulzi DJ, Yazer MH: Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52:160–165
13. Li G, Rachmale S, Kojicic M, et al.: Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51:338–343
14. Watson GA, Sperry JL, Rosengart MR, et al.: Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67:221–227
15. Bochicchio GV, Napolitano L, Joshi M, et al.: Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study. World J Surg 2008; 32:2185–2189
16. Sperry JL, Ochoa JB, Gunn SR, et al.: An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65:986–993
17. Eder AF, Herron R, Strupp A, et al.: Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47:599–607
18. Vamvakas EC, Blajchman MA: Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24:77–124
19. vanEerd MC, Mario Ouwens JN, de Peuter MA: Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG(R)) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. Transfus Apher Sci 2010; 43:251–259
20. Blumberg N, Heal JM: Mortality risks, costs, and decision making in transfusion medicine. Am J Clin Pathol 2000; 114:934–937
21. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012. Silver Spring, MD, US Food and Drug Administration, 2013
22. Pahuja S, Sethi N, Singh S, et al.: Concurrent audit of fresh frozen plasma: experience of a tertiary care hospital. Hematology 2012; 17:306–310
23. US Department of Health and Human Services: National Blood Collection and Utilization Survey Report 2011. 2013; http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf
24. Stanworth SJ, Grant-Casey J, Lowe D, et al.: The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011; 51:62–70
25. Tinmouth A, Thompson T, Arnold DM, et al.: Utilization of frozen plasma in Ontario: a provincewide audit reveals a high rate of inappropriate transfusions. Transfusion 2013; 53:2222–2229
26. Sheikholeslami H, Kani C, Fallah-Abed P, et al.: Transfusion audit of blood products using the World Health Organization Basic Information Sheet in Qazvin, Islamic Republic of Iran. East Mediterr Health J 2010; 16:1257–1262
27. Collins RA, Wisniewski MK, Waters JH, et al.: Effectiveness of multiple initiatives to reduce blood component wastage. Am J Clin Pathol 2015; 143:329–335
28. Borkent-Raven BA, Janssen MP, van der Poel CL, et al.: The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010; 99:54–64
29. Bloch EM, Cohn C, Bruhn R, et al.: A cross-sectional pilot study of blood utilization in 27 hospitals in northern california. Am J Clin Pathol 2014; 142:498–505
30. Henseler O: Report on notifications pursuant to Section 21 TFG (German Transfusion Act) for 2012 and 2013. 2013; http://www.pei.de/EN/information/blood-supply/reports/report-blood-supply-2012-2013-21tfg-content.html?nn=3251266.
31. -TRIP annual report 2012 Hemovigilance-Extended version. 2012; http://www.tripnet.nl/pages/en/documents/TRIP2012Hemovigilantie_ENGELS4.pdf.
32. Karam O, Tucci M, Combescure C, et al.: Plasma transfusion strategies for critically ill patients. Cochrane Database Syst Rev 2013; 12:CD010654
33. Yang L, Stanworth S, Hopewell S, et al.: Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials (CME). Transfusion 2012; 52:1673–1686
34. Roback JD, Caldwell S, Carson J, et al.: Evidence-based practice guidelines for plasma transfusion. Transfusion 2010; 50:1227–1239
35. Hofmann A, Ozawa S, Farrugia A, et al.: Economic considerations on transfusion medicine and patient blood management. Best Pract Res Clin Anaesthesiol 2013; 27:59–68
36. Shander A, Hofmann A, Ozawa S, et al.: Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50:753–765
37. Joseph B, Aziz H, Pandit V, et al.: Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference? World J Surg 2014; 38:1875–1881
38. Toner RW, Pizzi L, Leas B, et al.: Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services. Appl Health Econ Health Policy 2011; 9:29–37
39. Wehrli G, Taylor NE, Haines AL, et al.: Instituting a thawed plasma procedure: it just makes sense and saves cents. Transfusion 2009; 49:2625–2630
40. Blanchette CM, Wang PF, Joshi AV, et al.: Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J 2007; 16:353–363
41. Spalding GJ, Hartrumpf M, Sierig T, et al.: Cost reduction of perioperative coagulation management in cardiac surgery: value of “bedside” thrombelastography (ROTEM). Eur J Cardiothorac Surg 2007; 31:1052–1057
42. Varney SJ, Guest JF: The annual cost of blood transfusions in the UK. Transfus Med 2003; 13:205–218
43. Williamson LM, Devine DV: Challenges in the management of the blood supply. Lancet 2013; 381:1866–1875
44. Haldiman L, Zia H, Singh G: Improving appropriateness of blood utilization through prospective review of requests for blood products: the role of pathology residents as consultants. Lab Med 2014; 45:264–271
45. Leahy MF, Roberts H, Mukhtar SA, et al.: A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion 2014; 54:1133–1145
46. Goodnough LT, Hill CC: Use of point-of-care testing for plasma therapy. Transfusion 2012; 52(Suppl 1):56S–64S
47. Theusinger OM, Felix C, Spahn DR: Strategies to reduce the use of blood products: a European perspective. Curr Opin Anaesthesiol 2012; 25:59–65
48. Seltsam A, Muller TH: Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162:442–454
49. Schöchl H, Nienaber U, Maegele M, et al.: Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83
50. Innerhofer P, Westermann I, Tauber H, et al.: The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013; 44:209–216